Tunable Library Architectures
Control stability, diversity, and paratope exploration based on your target class and screening goals.
Antibody Discovery Platforms
Built to generate decision-ready antibody binders in weeks
DuneX Biosciences deploys human scFv and VHH nanobody libraries through FACS-based yeast display workflows for rapid binder discovery, clone ranking, and affinity maturation.
108-109Library Diversity
>3FACS Enrichment Rounds
3-6 weeksTypical Discovery Campaign
5-20Prioritized Output Clones
FACSQuantitative Screening
Platform Advantages
What makes our yeast display platforms different
Built for practical antibody discovery campaigns where selection pressure, target biology, and downstream decision-making all matter.
Multi-Mode Selection Strategies
Match selection pressure to affinity, specificity, epitope competition, off-rate behavior, or downstream use.
FACS-Driven Precision Screening
Quantitative sorting enables controlled enrichment, specificity filtering, and better hit quality.
Designed for Real Discovery
Generate sequence-aware binder panels that can move into validation, ranking, reformatting, or affinity maturation.
Reproducible Screening Framework
Consistent selection workflows support reliable comparison across campaign rounds and follow-on iterations.
Library Architecture
Human scFv and VHH libraries for different discovery problems.
Modular library designs enable systematic control over stability, diversity, and epitope accessibility.
Library strategy directly impacts hit rate, epitope coverage, clone diversity, and downstream success.
How to choose a library strategy
- Use Constrained / Core designs for fast, stable binder discovery.
- Use Intermediate / Extended designs to increase hit diversity and epitope coverage.
- Use Coop variants when flexibility and epitope exploration matter.
- Use Nano-Deep™ when targeting cryptic, recessed, or pocket-like epitopes.
DuneX-Nova™
Human scFv Libraries
Nova™ libraries tune CDR-H3 length and L3 design to balance paratope stability, exploration depth, and screening behavior.
| Library Variant | H3 Length | L3 Design | Design Rationale | Best For |
|---|---|---|---|---|
| Nova-Constrained™ | 11 aa | Fixed | High stability and low conformational noise. | Fast screening and routine targets. |
| Nova-Constrained-Coop™ | 11 aa | Diversified | Introduces cooperative L3 flexibility. | Balanced stability and diversity. |
| Nova-Intermediate™ | 13 aa | Fixed | Balanced default architecture. | General discovery programs. |
| Nova-Intermediate-Coop™ | 13 aa | Diversified | Expanded conformational exploration. | Higher hit-rate discovery goals. |
| Nova-Extended™ | 15 aa | Fixed | Longer H3 for complex epitope access. | Difficult targets. |
| Nova-Extended-Coop™ | 15 aa | Diversified | Maximum conformational search space. | High-difficulty projects. |
DuneX-Nano™
VHH / Nanobody Libraries
Nano™ libraries are designed for compact binders, difficult epitopes, modular formats, and deep surface access.
| Library Variant | CDR3 Design | Structural Feature | Functional Advantage | Best For |
|---|---|---|---|---|
| Nano-Core™ | 13 aa | Standard length. | Stable, expressive, and low background. | Routine screening. |
| Nano-Extended™ | 15 aa | Extended loop. | Higher conformational diversity. | More difficult targets. |
| Nano-Deep™ | 15 aa + aromatic enrichment | Aromatic-enriched CDR3. | Enhanced deep-epitope engagement. | Cryptic and pocket targets. |
Selection Workflow
FACS-based yeast display selection and screening workflow
01
Library incubation with labeled antigenTarget format and detection strategy are reviewed before selection begins.
02
FACS-based enrichment and gatingQuantitative sorting supports controlled enrichment and specificity decisions.
03
Iterative selection across multiple roundsSelection pressure can be tuned as enrichment behavior emerges.
04
Clone recovery and sequence identificationRecovered binders are advanced into sequence-aware panel prioritization.
Selection pressure is actively tuned across rounds to control affinity, specificity, off-rate behavior, and epitope selection outcomes.
Data Confidence
Output quality and data confidence
Discovery programs are structured around outputs a biotech team can interpret, compare, and use for next-step decisions.
Quantitative Screening
Flow cytometry-based screening helps quantify enrichment behavior and clone-level binding signals.
Clear Enrichment Trends
Round-by-round selection behavior helps teams understand campaign progression.
Sequence-Diverse Panels
Recovered binders can be reviewed with sequence diversity and redundancy in mind.
Screening-Level Binding Signals
Clone panels are prioritized using practical binding behavior, not only recovery frequency.
Reformat Compatibility
Discovery outputs can support downstream IgG, Fc fusion, or soluble binder paths.
Outputs are structured to support go/no-go decisions, not just exploratory screening results.
Designed to produce interpretable, decision-ready antibody discovery data.
Use Cases
When teams typically use DuneX platforms
DuneX platforms are strongest when teams need fast, practical antibody or nanobody discovery without immunization timelines.
When early binder signals are needed to validate a target
Move from target concept toward prioritized binder panels.
When difficult or conserved targets need broader library search
Use broader or deeper library architectures when standard approaches are limiting.
When epitope diversity must be explored before lead selection
Screen across formats to expand binder behavior and surface coverage.
When rapid hit generation is needed without immunization
Compress early discovery timelines with yeast display selection workflows.
Supporting Biotech Teams Worldwide from the San Francisco Bay Area
Share your target format, project goal, and desired binder profile. We’ll help map the fastest practical path toward a focused yeast display discovery campaign.
Contact Us